497 related articles for article (PubMed ID: 29543066)
1. The role of IDH mutations in acute myeloid leukemia.
Montalban-Bravo G; DiNardo CD
Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066
[TBL] [Abstract][Full Text] [Related]
2. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
3. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
Nassereddine S; Lap CJ; Haroun F; Tabbara I
Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
[TBL] [Abstract][Full Text] [Related]
4. [Research Progress of Isocitrate Dehydrogenase Mutation-Positive Acute Myeloid Leukemia --Review].
Ye F; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):630-633. PubMed ID: 38660877
[TBL] [Abstract][Full Text] [Related]
5. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
6. Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.
Becker JS; Fathi AT
Curr Cancer Drug Targets; 2020; 20(7):490-500. PubMed ID: 32329690
[TBL] [Abstract][Full Text] [Related]
7. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
Upadhyay VA; Brunner AM; Fathi AT
Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Dang L; Su SM
Annu Rev Biochem; 2017 Jun; 86():305-331. PubMed ID: 28375741
[TBL] [Abstract][Full Text] [Related]
11. IDH Inhibitors in AML-Promise and Pitfalls.
McMurry H; Fletcher L; Traer E
Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
[TBL] [Abstract][Full Text] [Related]
12. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
13.
Babakhanlou R; DiNardo C; Borthakur G
Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
[TBL] [Abstract][Full Text] [Related]
14. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
Sharma H
Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
[TBL] [Abstract][Full Text] [Related]
15. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
[TBL] [Abstract][Full Text] [Related]
18. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Chaturvedi A; Herbst L; Pusch S; Klett L; Goparaju R; Stichel D; Kaulfuss S; Panknin O; Zimmermann K; Toschi L; Neuhaus R; Haegebarth A; Rehwinkel H; Hess-Stumpp H; Bauser M; Bochtler T; Struys EA; Sharma A; Bakkali A; Geffers R; Araujo-Cruz MM; Thol F; Gabdoulline R; Ganser A; Ho AD; von Deimling A; Rippe K; Heuser M; Krämer A
Leukemia; 2017 Oct; 31(10):2020-2028. PubMed ID: 28232670
[TBL] [Abstract][Full Text] [Related]
19. Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
Waitkus MS; Diplas BH; Yan H
Cancer Cell; 2018 Aug; 34(2):186-195. PubMed ID: 29805076
[TBL] [Abstract][Full Text] [Related]
20. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
